173 related articles for article (PubMed ID: 17606754)
1. HER2 status in breast cancer--an example of pharmacogenetic testing.
Kroese M; Zimmern RL; Pinder SE
J R Soc Med; 2007 Jul; 100(7):326-9. PubMed ID: 17606754
[TBL] [Abstract][Full Text] [Related]
2. [Assessment of HER2 status in breast cancer].
Penault-Llorca F; Cayre A
Bull Cancer; 2004 Dec; 91 Suppl 4():S211-5. PubMed ID: 15899610
[TBL] [Abstract][Full Text] [Related]
3. [HER2 testing in breast cancer].
Yoshimura K
Nihon Rinsho; 2007 Jun; 65 Suppl 6():275-80. PubMed ID: 17682167
[No Abstract] [Full Text] [Related]
4. New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.
Sakamoto G; Mitsuyama S
Breast Cancer; 2000; 7(4):350-7. PubMed ID: 11114864
[No Abstract] [Full Text] [Related]
5. HER2--a discussion of testing approaches in the USA.
Thor A
Ann Oncol; 2001; 12 Suppl 1():S101-7. PubMed ID: 11521714
[TBL] [Abstract][Full Text] [Related]
6. HER2 testing recommendations in Australia.
Bilous M;
Pathology; 2001 Nov; 33(4):425-7. PubMed ID: 11827407
[TBL] [Abstract][Full Text] [Related]
7. Saving lives with accurate HER2 testing.
Ross JS
Am J Clin Pathol; 2010 Aug; 134(2):183-4. PubMed ID: 20660318
[No Abstract] [Full Text] [Related]
8. Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab).
Umemura S; Sakamoto G; Sasano H; Tsuda H; Akiyama F; Kurosumi M; Tokuda Y; Watanabe T; Toi M; Hasegawa T; Osamura RY
Breast Cancer; 2001; 8(4):316-20. PubMed ID: 11791124
[TBL] [Abstract][Full Text] [Related]
9. HER2 testing and correlation with efficacy of trastuzumab therapy.
Konecny G; Slamon DJ
Oncology (Williston Park); 2002 Nov; 16(11):1576, 1578. PubMed ID: 12469932
[No Abstract] [Full Text] [Related]
10. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.
Chorn N
Oncol Nurs Forum; 2006 Nov; 33(2):265-72. PubMed ID: 16518442
[TBL] [Abstract][Full Text] [Related]
11. [HER2 ASCO guidelines. The answer to everything?].
Burandt E; Sauter G
Pathologe; 2010 Oct; 31 Suppl 2():285-91. PubMed ID: 20740285
[TBL] [Abstract][Full Text] [Related]
12. HER-2 and fluorescent in situ hybridization to evaluate breast cancer.
Tanvetyanon T
JAMA; 2004 Jul; 292(3):328; author reply 328-9. PubMed ID: 15265845
[No Abstract] [Full Text] [Related]
13. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.
O'Malley FP; Thomson T; Julian J; Have C; Cosby R; Gelmon K; Andrulis I; Whelan T
Arch Pathol Lab Med; 2008 Jan; 132(1):61-5. PubMed ID: 18181675
[TBL] [Abstract][Full Text] [Related]
14. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?
Yaziji H; Gown AM
Hum Pathol; 2004 Feb; 35(2):143-6. PubMed ID: 14991529
[No Abstract] [Full Text] [Related]
15. HER-2 status determination in breast carcinomas. A practical approach.
García-Caballero T; Menéndez MD; Vázquez-Boquete A; Gallego R; Forteza J; Fraga M
Histol Histopathol; 2006 Mar; 21(3):227-36. PubMed ID: 16372244
[TBL] [Abstract][Full Text] [Related]
16. HER2 testing and correlation with efficacy of trastuzumab therapy.
Fornier M; Risio M; Van Poznak C; Seidman A
Oncology (Williston Park); 2002 Oct; 16(10):1340-8, 1351-2; discussion 1352, 1355-8. PubMed ID: 12435204
[TBL] [Abstract][Full Text] [Related]
17. The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management.
Striebel JM; Bhargava R; Horbinski C; Surti U; Dabbs DJ
Am J Clin Pathol; 2008 Mar; 129(3):383-90. PubMed ID: 18285260
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing.
Hicks DG; Kulkarni S
Arch Pathol Lab Med; 2008 Jun; 132(6):1008-15. PubMed ID: 18517261
[TBL] [Abstract][Full Text] [Related]
19. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.
Paik S; Bryant J; Tan-Chiu E; Romond E; Hiller W; Park K; Brown A; Yothers G; Anderson S; Smith R; Wickerham DL; Wolmark N
J Natl Cancer Inst; 2002 Jun; 94(11):852-4. PubMed ID: 12048273
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor 2 testing recommendation.
Raji A; Lurie RH
Arch Pathol Lab Med; 2007 Sep; 131(9):1330-1; author reply 1331-3. PubMed ID: 17824785
[No Abstract] [Full Text] [Related]
[Next] [New Search]
